Market Call

Julien Nono-Womdim outlines market correction, sector rotation, and specific stock picks in AI and healthcare.

46 min Listen to the original Episode page
Market CorrectionAI SpendingHealthcareValuationGeopoliticsCybersecurityBiotechConsumer Staples

Summary

Julien Nono-Womdim discusses the current market correction, noting the Nasdaq 100 is in correction territory and over half the S&P 500 is in bear market. He attributes this to interest rate concerns, geopolitical tensions, and AI spending doubts. He highlights a shift in valuation attractiveness compared to mid-2026, favoring healthcare and select tech. Specific holdings include Costco, Uber, Netflix, StoneX, Eli Lilly, and Merck. He also discusses Google, TG Therapeutics, MedPace, and United Natural Foods.

Key takeaways

  1. 1
    tech heavy Nasdaq 100, it's in correction territory, down more than 10% off its highs. If you look at the SP 500, not as bad, down only 3 to 5% off its highs. But within the index itself, more than 50% of its members are actually down more than 20%, meaning in bear market territory.

    Unidentified speaker (speaker_1) · 0:50

  2. 2
    Geopolitical resolution in Europe and the Middle East was expected earlier in 2026 but has not occurred, contributing to market volatility.

    Unidentified speaker (speaker_1) · 1:10

  3. 3
    In June or July of that? this year, the answer was firmly no. Today, that answer is increasingly becoming yes.

    Unidentified speaker (speaker_1) · 3:02

  4. 4
    Costco trades at over 40 times earnings, which the speaker considers a demanding valuation.

    Unidentified speaker (speaker_1) · 5:14

  5. 5
    The 'Henry Ford effect' is cited: industrial activity is a function of consumer activity because consumers buy the products.

    Unidentified speaker (speaker_1) · 7:24

Episode sections

  1. 0:46 – 1:49

    Market Overview and Macro Risks

    Julien Nono-Womdim notes the Nasdaq 100 is in correction territory (down >10%) and over 50% of S&P 500 members are in bear market territory (>20% decline). He attributes this to interest rate concerns, geopolitical tensions in Europe/Middle East, and doubts about AI spending sustainability.

  2. 1:49 – 4:11

    Bull vs. Bear Case and Valuation Shift

    The bear case cites runaway inflation from Middle East conflicts and AI multiple/earnings compression. The bull case highlights sustainable earnings in AI and healthcare, with a shift in stock picking opportunities as valuations become attractive compared to June/July 2026.

  3. 4:11 – 7:50

    Costco Analysis: Hold Due to Valuation

    Costco is rated a hold. While the consumer is doing well, the valuation is deemed demanding at >40x earnings. The speaker notes the economy is driven by industrial investment rather than consumer spending, linking consumer weakness to potential industrial slowdowns via the Henry Ford effect.

  4. 7:50 – 11:05

    ServiceNow: Sidelines Due to AI Uncertainty

    ServiceNow is on the sidelines due to uncertainty over customer willingness to spend on new seats and potential erosion of pricing power in an AI world. The speaker contrasts this with CrowdStrike, which is owned and liked due to increased cybersecurity needs from agentic AI.

  5. 11:05 – 13:39

    Uber: Hold Despite Autonomous Vehicle Concerns

    Uber is held because the stock underperformance is due to sector weakness and anxiety over autonomous vehicles (e.g., Tesla), not fundamentals. The speaker believes Uber will benefit from autonomous tech and values its routing algorithms and diversified services.

  6. 13:39 – 18:05

    Netflix: Transition to Value Play

    Netflix is transitioning from a growth to a value stock due to saturated US markets and lower international profitability. The speaker finds it attractive at ~17x earnings for a moderate-growth, capital-intensive business, waiting for multiple compression to ~40-45x for entry.

  7. 18:05 – 19:38

    StoneX: Trimmed Position After Run-Up

    StoneX is owned but position was trimmed due to valuation increases. The company benefits from volatility and acquisitions. The speaker expects creative value from consolidating acquired back offices and sees continued upside despite the recent run-up.

  8. 19:38 – 35:50

    Healthcare Sector: AI-Enabled Innovation

    Healthcare is viewed positively due to AI enabling innovation (trial/error simulation) and geopolitical refuge status. Eli Lilly is owned for its strong execution and moat beyond GLP-1s. Merck is viewed optimistically regarding its ability to replace Keytruda revenues.

  9. 35:50 – 37:05

    Google/Alphabet AI and Consumer Data Strength

    Speaker 1 argues Google's differentiation lies in its consumer data stack and TPUs, positioning it as a strong winner in the AI ecosystem despite concerns about search cannibalization or YouTube shifts. The speaker views Google's franchise as currently under-monetized with significant reserve pricing power.

  10. 37:05 – 39:40

    Billionaire Selling Activity and Investment Horizons

    Speaker 0 notes that billionaires, including Stanley Druckenmiller's family office, sold Alphabet Class A shares in Q3. Speaker 1 dismisses this as indicative of Druckenmiller's high-turnover style rather than a fundamental view on Google's medium-to-long-term prospects, suggesting retail investors can find alpha in patience.

  11. 39:40 – 43:05

    TG Therapeutics (TGTX) and Briumvi for MS

    Speaker 1 highlights TGTX as a top pick due to its drug Briumvi, an anti-CD20 therapy for multiple sclerosis (MS). The speaker notes the MS market is growing mid-single digits, while the anti-CD20 category grows over 20%, and TGTX is approaching a $1 billion run rate revenue.

  12. 43:05 – 45:03

    MedPace Holdings (MEDP) as a CRO Play

    Speaker 1 identifies MEDP as a key investment in the biotech ecosystem, noting that outsourcing clinical research to CROs is a structural trend. MEDP is favored for serving smaller biotechs, with bullishness driven by recovered biopharma spending and justified premium valuation.

  13. 45:03 – 46:03

    United Natural Foods (UNFI) Organic Distribution

    Speaker 1 briefly mentions UNFI as an organic food distributor with Whole Foods as a core customer. The investment thesis relies on shifting consumer preferences toward organic products, with detailed analysis available on Goodreid's website.

Assets discussed

AssetKindStanceContext
S&P 500indexbearishIf you look at the SP 500, not as bad, down only 3 to 5% off its highs.
MicrosoftMSFTequitybullishbut ultimately Microsoft has the enterprise customer and serves a whole host of functions within the enterprise. It is highly unlikely that a CTO removes Microsoft with other providers that have piecemeal solutions.
AppleAAPLequitybullishOkay. Another email. The inbox, Sue in Chatham, Ontario asks, is Apple too expensive from a valuation perspective?

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

The Nasdaq 100 is in correction territory, down more than 10% off its highs.

Unidentified speaker (UNKNOWN) ·0:50

How to verify: Check Nasdaq 100 index performance data from Bloomberg or Yahoo Finance for the period Nov 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

More than 50% of S&P 500 members are down more than 20% off their highs.

Unidentified speaker (speaker_1) ·1:10

How to verify: Check S&P 500 sector/market cap weighted performance distribution from S&P Global or Bloomberg for Nov 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Costco trades at north of 40 times earnings.

Unidentified speaker (speaker_1) ·5:14

How to verify: Check Costco (COST) trailing twelve-month P/E ratio on Yahoo Finance or Morningstar for Nov 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Netflix trades at approximately 17 times earnings.

Unidentified speaker (speaker_1) ·15:23

How to verify: Check Netflix (NFLX) trailing P/E ratio on Yahoo Finance or Morningstar for Nov 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

CrowdStrike is owned by Goodreid Investment Counsel.

Unidentified speaker (speaker_1) ·9:49

How to verify: Check Goodreid Investment Counsel's public portfolio disclosures or 13F filings if applicable, or press releases from Nov 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Merck's Keytruda accounts for forty percent of revenues.

Unidentified speaker (speaker_1) ·24:41

How to verify: Check Merck (MRK) annual reports (10-K) or investor presentations for revenue breakdown by product. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Apple published a paper two years ago stating LLMs are not intelligent.

Unidentified speaker (UNKNOWN) ·34:02

How to verify: Search for Apple internal research papers or public statements from 2026 regarding LLM intelligence. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

StoneX is a financial services company that does trading on behalf of clients in commodities and FX.

Unidentified speaker (speaker_1) ·18:25

How to verify: Check StoneX (SNX) company profile on their investor relations page or Wikipedia. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Celestica did a small equity raise later in the year.

Unidentified speaker (speaker_1) ·26:30

How to verify: Check Celestica (CLS) SEC filings (8-K or S-3) for equity offerings in 2026. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Google has a differentiated consumer data stack and TPUs, positioning it as a strong winner in the AI ecosystem.

Unidentified speaker (speaker_1) ·35:50

How to verify: Review Google's (Alphabet) investor presentations on TPUs and AI infrastructure; check earnings reports for AI-related revenue or investment disclosures. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Stanley Druckenmiller's family office sold every Alphabet Class A share in Q3.

Unidentified speaker (speaker_0) ·37:05

How to verify: Check SEC Form 13F filings for Stanley Druckenmiller's family office (Duquesne Family Office) for the Q3 2026 reporting period. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

About 2.9 million people globally have multiple sclerosis, with about one million in the US.

Unidentified speaker (speaker_1) ·40:09

How to verify: Consult global health statistics from the World Health Organization (WHO) or the National Multiple Sclerosis Society. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

The anti-CD20 drug category is growing in the 20% plus range.

Unidentified speaker (UNKNOWN) ·41:20

How to verify: Analyze market research reports from healthcare data providers (e.g., IQVIA, EvaluatePharma) on the growth rate of the anti-CD20 therapeutic segment. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

TG Therapeutics is approaching a billion-dollar run rate revenue.

Unidentified speaker (UNKNOWN) ·41:20

How to verify: Review TG Therapeutics' (TGTX) quarterly earnings reports and revenue guidance for the relevant period. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

TG Therapeutics raised revenue guidance to about $1 billion above consensus estimates in their last earnings announcement.

Unidentified speaker (speaker_0) ·42:19

How to verify: Check TG Therapeutics' (TGTX) latest earnings press release and compare guidance to consensus estimates from financial data providers like Bloomberg or FactSet. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

MedPace is a CRO that helps biopharma companies conduct phase one through phase four clinical trials.

Unidentified speaker (speaker_1) ·43:10

How to verify: Review MedPace Holdings' (MEDP) corporate website and investor presentations detailing their service offerings and trial phases. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Biopharma spending has recovered, with positive indications from VC spending.

Unidentified speaker (speaker_1) ·44:39

How to verify: Review industry reports on biopharma R&D spending and venture capital investment trends in biotech from sources like BioPharma Dive or PitchBook. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

United Natural Foods has Whole Foods as a core customer.

Unidentified speaker (speaker_1) ·45:03

How to verify: Check United Natural Foods' (UNFI) SEC filings (e.g., 10-K) for customer concentration disclosures. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.

Primary source

Do your own research

  • Verify Nasdaq 100 and S&P 500 performance data for November 2026 via Bloomberg Terminal or Yahoo Finance historical data.
  • Check S&P Capital IQ healthcare sector earnings growth forecasts for 2026-2027 to assess sustainability claims.
  • Review US Bureau of Economic Analysis (BEA) GDP component data for 2021-2026 to confirm shift from consumer-led to industrial-led growth.
  • Examine Costco (COST) trailing PE ratio via Yahoo Finance or Morningstar to verify valuation claims.
  • Analyze CrowdStrike (CRWD) investor presentations or cybersecurity industry reports on agentic AI threats to validate cybersecurity demand.
  • Check S&P 500 PE ratio trends from June/July 2026 to November 2026 to assess valuation shift claims.
  • Review TG Therapeutics (TGTX) pipeline updates and phase three readout status for Briumvi subcutaneous use.
  • Verify MedPace (MEDP) valuation premiums and biopharma spending trends to assess CRO outsourcing structural trend claims.
Full transcriptexpand

0:09Unidentified speaker (speaker_0): Hello, I'm Christine Lee. Welcome to Market Call. Julian Nanon Wadin is on the show with us today. He's vice president at Goodread Investment Council and will be taking your questions on U.S. equities. Call us toll-free at 1-855-326-6266 or send us an email to marketcall at DNNbloomberg.ca.

0:31Unidentified speaker (UNKNOWN): All right,

0:31Unidentified speaker (speaker_0): Julian, welcome to the show. So we're seeing a lot of red in the markets today. The Toronto Stock Exchange, as well as the SP 500, the Nasdaq, are headed for a fifth straight day of losses.

0:42Unidentified speaker (UNKNOWN): Right.

0:43Unidentified speaker (speaker_0): What's the damage beneath the surface here?

0:46Unidentified speaker (speaker_1): Well, the damage has been certainly widespread. If you look at

0:50Unidentified speaker (UNKNOWN): the

0:50Unidentified speaker (speaker_1): tech heavy Nasdaq 100, it's in correction territory, down more than 10% off its highs. If you look at the SP 500, not as bad, down only 3 to 5% off its highs. But within the index itself, more than 50% of its members are actually down more than 20%, meaning in bear market territory. And from our perspective at Goodread, that's a function of concerns around interest rates, the geopolitical picture in Europe, in the Middle East, which many, including us, had thought would reach a resolution sooner, earlier in the year, and that hasn't been the case. And of course, concerns around the sustainability of AI spending and the kind of returns uh the hyperscalers and the Frontier Labs are getting on that space. spending.

1:40Unidentified speaker (UNKNOWN): So

1:40Unidentified speaker (speaker_0): the question on a lot of people's minds is: is this a temporary correction or a signal of something more systemic as in recession territory?

1:49Unidentified speaker (UNKNOWN): Well,

1:50Unidentified speaker (speaker_1): as it always is in markets, the answer is never straightforward. I'd say we have to balance the bullish in the bear case and then pick pick a side. So maybe what we'll start with the bear case. Um runaway inflation is one of them, right? To the extent that the war persists in the Middle East, the Strait of Hormuz remains closed, the Fed will be forced to continue hiking interest rates. To the extent that AI spending has potentially peaked, or whether or not we see a slowdown in the future, that will have to drive further multiple compression. and earnings compression. And so those are some of the things that are concerning from a bearish point of view. From a bullish point of view, when you look at the earnings backdrop, certainly in the AI ecosystem,

2:42Unidentified speaker (UNKNOWN): you

2:42Unidentified speaker (speaker_1): ask yourself: well, is it sustainable from our perspective? It is certainly sustainable. You look at other sectors that are starting to participate healthier. healthcare, we think earnings growth there is certainly sustainable. But more importantly, for us as stock pickers, the path forward is generally dictated by: can we actually find opportunities? When you turn on your Bloomberg, you go through the different companies that you cover, are you seeing things that are trading at attractive valuations relative to their growth prospects? In June or July of that? this year, the answer was firmly no. Today, that answer is increasingly becoming yes. And so for us, we're certainly very excited, excited about the prospects of some of the companies that we own, and certainly about the increase in opportunity set from a stock picking perspective.

3:32Unidentified speaker (speaker_0): All right, well, we'll dive into what some of your picks and what your thoughts are on some stocks later on the show. We'll be back with Julian Nono Wamdeam. He's the uh good invest good read investment counsel taking your questions on U.S. equities. Welcome back to Market Call. Let's check in on the inboxes. We have an email from Robert. He asks, is Costco a current buy, sell, or hold?

4:11Unidentified speaker (UNKNOWN): Hi,

4:12Unidentified speaker (speaker_1): Robert. Thank you for the question. Um, we don't own Costco. From our perspective, we'd probably consider it a hold. The reason being

4:21Unidentified speaker (UNKNOWN): uh

4:21Unidentified speaker (speaker_1): first,

4:23Unidentified speaker (UNKNOWN): the

4:23Unidentified speaker (speaker_2): lights are twinkling, the playlist sparkling. IHeart

4:29Unidentified speaker (UNKNOWN): the

4:29Unidentified speaker (speaker_2): Holidays is here. Canada's home for Christmas music with nonstop festive favorites 24-7. Turn it up and unwrap the holidays everywhere you go. Just ask your smart speaker to play iHeart the Holidays or stream it anytime. anywhere, on the free iHeartRadio app.

4:54Unidentified speaker (UNKNOWN): Uh

4:55Unidentified speaker (speaker_1): the US consumer is generally doing okay. We we think the consumer is doing well. Sentiment is weak. Consumer sentiment is weak because of some of the geopolitical macro factors that are happening. Uh, but the consumer is generally okay, and we think Costco is doing reasonably well. Where we pause a little bit, and that's been sort of a perennial debate, is on the valuation at north of 40 times earnings. We think the valuation is demanding. And the market has gravitated towards Costco in recent months as a place of refuge amidst the volatility. So medium, short to medium term hold, longer term, we acknowledge the quality of the company.

5:38Unidentified speaker (speaker_0): Does this play into your bullish case scenario where the weakness and consumer sentiment could play a factor in weakening the economy?

5:47Unidentified speaker (speaker_1): Yeah, so the economy is has like these different layers of reflexivity where one factor influences the other, which then influences that uh initial factor. Historically, if you go back 10, 15, 20 years, uh many investors we grew up in this world of a consumer-led economy. The consumer does well, home buying activity, the retail sector is very strong, and that drives consumer behavior spending, which feeds the economy, and that eventually feeds equities. Over the last three to five years, what's been driving the economy hasn't been the consumer, it's been industrial. investment, uh, certainly in the US but even globally. Some of that is AI, some of that is uh

6:34Unidentified speaker (UNKNOWN): r

6:34Unidentified speaker (speaker_1): uh onshoring. And so if the consumer weakens, because ultimately the consumer is part of the industrial economy, then that consumer may in turn lead to less domestic investment. In other words, if enterprise is not willing to spend on AI because there's less seats or demand isn't strong, um, then investments in AI ultimately slow down. I I uh a few months ago I I had a conversation with Gord at in at our office and and he reminded me of the the Henry Ford effect. Have you have you heard of it?

7:14Unidentified speaker (speaker_0): Uh Tell me more.

7:17Unidentified speaker (speaker_1): Henry Ford says, uh said, I I pay my employees well because ultimately they're the ones that buy the cars.

7:24Unidentified speaker (speaker_0): Yeah.

7:24Unidentified speaker (speaker_1): And so auto sales are a function of general salaries. Industrial activity is also a function of consumer activity.

7:33Unidentified speaker (speaker_0): Okay. All right. Well, we watch Costco. We've got a caller on the line. We've let's hear from Jazz and Nil. in Milton, Ontario. Jazz, hello.

7:41Unidentified speaker (speaker_3): Hi, uh, my question is on ServiceNow. It's fallen quite a lot since uh the last earnings report. And uh just wondering if I can get your thoughts on this. Thank you.

7:50Unidentified speaker (speaker_1): Yeah, I appreciate it. Um so we're on the sidelines on ServiceNow. We're we're well, we think once the AI dust settles and this idea that software is dead settles, we think it's a it's an interesting uh area uh for research purposes. We're we're we're on the sidelines because we don't know the extent to which customers are going to be willing to spend um on on on new seats,

8:19Unidentified speaker (UNKNOWN): um

8:19Unidentified speaker (speaker_1): what kind of pricing power ServiceNow is going to have in the future. If you go back five years or so, the algorithm was quite simple. You get more seats, and then you have incremental pricing power each year.

8:33Unidentified speaker (UNKNOWN): In

8:33Unidentified speaker (speaker_1): an AI world, that paradigm has changed a little bit. That's not to suggest that ServiceNow is going to be completely disintermediated. What we need to first figure out is whether or not the company can be sustainably profitable. and have some degree of pricing power in a world where there are going to be alternatives, whether it's from smaller companies that target niche industries or from internal IT teams that decide to build in house solutions because ServiceNow Now, or where other service providers are becoming cost prohibitive.

9:12Unidentified speaker (UNKNOWN): Right.

9:12Unidentified speaker (speaker_0): So ServiceNow is an a enterprise IT. provider. Correct. We're seeing a lot of shutdowns in technology from Microsoft to the flights to banks. I don't know if you see any any relation to this in stock performance.

9:29Unidentified speaker (speaker_1): So, yes. So in recent weeks, we've seen a number of let's call them IT disruptions, and and and that certainly there's a concern that some of that may have to do with cybersecurity. There isn't any concrete sort of definitive answers to what's driving these various events that are happening right now. Within our portfolios, we own CrowdStrike, uh, which is a cybersecurity company. Uh, we've done extremely well on it. We continue to like it, and our view is very simple.

9:59Unidentified speaker (UNKNOWN): Um,

9:59Unidentified speaker (speaker_1): the advances in AI are going to make it easier for cybersecurity attacks to happen. Number one. Number two, agentic AI means there's going to be more people, people in air quotes, because agents, sort of going through your website, more traffic activity. Because of that increased traffic, uh cybersecurity becomes uh even more important. So we we own we own crowd. CrowdStrike uh for that reason. On ServiceNow, we think that there's potentially real erosion in pricing power for the company and so we're we're waiting on the sidelines.

10:37Unidentified speaker (speaker_0): All right. We've got another caller on the line, this one from Anita in Markham, Ontario. Anita, what's your question?

10:45Unidentified speaker (speaker_3): Ah Uh good afternoon. Thank you so much for taking my call. My question is on Uber. I I do own Uber and I've been holding on to it for a while. Um c uh could I have your thoughts on it please? Uh it doesn't seem to be going anywhere. Do you think do you would you recommend me holding on to it still or should I just sell it?

11:07Unidentified speaker (UNKNOWN): Hi

11:07Unidentified speaker (speaker_1): Anita, thank you very much for the question. Um so you're in good company. We we own serv s uh we own Uber as well. And you're right, the stock hasn't performed particularly well, not because the company isn't performing well in our view. We think there's sort of anxiety within the marketplace for two reasons. The first one being um what does Uber look like in an autonomous sort of vehicle world and where does the you know competition from the likes of Tesla with the uh cyber taxi and potentially others? So, what does Uber look like in a world of autonomous? And second, uh Uber is part of the industrial sector in the SP 500. And so the sector has been under pressure. ETFs and many other investors sort of wholesale. tend to sell the sector in groups, so it's it's benefiting from being in a it's hurting from being in a bad neighborhood at this moment. But from our perspective, fundamentally, the company is good. On the autonomous uh

12:15vehicle concern, we're not particularly concerned, and we think that to the extent that autonomous becomes a real solution, they'd end up being a beneficiary.

12:24Unidentified speaker (UNKNOWN): Um and

12:25Unidentified speaker (speaker_1): then on the adult industrial sector weakness, that will dissipate in time. What we think the true value of the company is the algorithms. The problem solving of routing traffic in terms of passenger and And and and uh Ride rides i is uh a differentiated from our perspective. And additionally, they have other services beyond just uh Uber Rides. So we we we like the company and we continue to hold it.

12:58Unidentified speaker (speaker_0): Interesting. I just see the headline Uber and China's Momentous Start Free Robo Taxi Trials in Munich. So it is a global, worldwide uh progressive technology that is taking on.

13:08Unidentified speaker (speaker_1): Correct. And they they'll they'll end up being a benef a beneficiary of it.

13:12Unidentified speaker (speaker_0): All right. We'll be back with Julian Nono Wamdim of Goodread Investment Council taking your questions on US equities after the break.

13:28Unidentified speaker (UNKNOWN): Welcome

13:28Unidentified speaker (speaker_0): back to Market Call. Let's head over to the inboxes. We've got an email from Greg who asks: what does the guest guests think about Netflix? I don't understand how they are turning any profit.

13:39Unidentified speaker (speaker_1): Thank you for the question, Greg. Not Netflix, how are they turning any profit?

13:48Unidentified speaker (speaker_0): Well, the streaming TV wars are just beginning. We're hearing from uh Netflix's uh chief executive.

13:56Unidentified speaker (speaker_1): Well, I so perhaps I'll I'll share our perspective on on Netflix. I think we don't own it. Um I think last time I was here, actually we we got a question on Netflix, and from our perspective, there's currently a transition in the shareholder base in the company from growth investors to value investors. That transition is natural and it's justified for a few reasons. Uh the first is if you look at the growth rates five or ten years ago, n Netflix was growing in the twenties, 20s, sometimes even in the 30s,

14:28Unidentified speaker (UNKNOWN): in

14:28Unidentified speaker (speaker_1): terms of percentage points of revenue growth. And that was them gaining market share penetration within the US market. You then went through a phase where the US market became saturated and then they expanded internationally. Today, as we look at the company, the growth rate has decelerated substantially because the biggest profit pool, which is the US consumer, is more or less fully penetrated. and the international customer is not as profitable. Additionally, as you were talking about, historically there was this view that the capital intensity of the business would eventually slow down. But with the streaming wars, what we're starting to see is that they will continuously have to invest in content, meaning the profitability of the business is much lower than perhaps its historical valuation justified. Where does that leave us today? Well, at 17 or so times earnings for a moderate to low growth business that is moderately capital intensive, shares aren't actually particularly unattractive. So we're starting to get interested because we do think that at

15:42a certain point the business will become too cheap relative to what's quality. And that quality is they're still able to garner eyeballs and attention with the content that they make.

15:55Unidentified speaker (speaker_0): Yeah, Netflix initiated or executed one of the biggest rounds of layoffs they've had in years. They're planning to expand into live events and sports. Do you see that as a sustainable growth avenue?

16:08Unidentified speaker (speaker_1): Well, we'll have to see how it's executed. Um, that area is also competitive. The layoffs are going to be margin accretive in the short term, but is that sustainable and is that worthy of material price appreciation? Uh I don't know. Um I'd say what we think is the dominant factor in terms of how well the shares will do is really how how much multiple compression do you see over the next few months? In the sort of sub-50, in the low to mid 40s, we think that the shares probably offer compelling value just because we think that the franchise has longevity, perhaps not growth as it once did, but it's it certainly has longevity. But this is one where you let price come to you. You don't necessarily um chase the stock simply because, as I said, no longer a growth story in our eyes.

17:04Unidentified speaker (UNKNOWN): All

17:04Unidentified speaker (speaker_0): right, let's head over to the phone lines. We have Nick on the line from Halgar, British Columbia. Nick, what's your question?

17:12Unidentified speaker (UNKNOWN): Hi

17:12Unidentified speaker (speaker_3): there, yeah. It's uh Castlegar BC. Um just wanted to get your take on Sandisc. Um just wondering if this is a good company to own and if so, is this a good entry point?

17:25Unidentified speaker (UNKNOWN): Yeah,

17:26Unidentified speaker (speaker_1): I think

17:26Unidentified speaker (UNKNOWN): uh

17:26Unidentified speaker (speaker_1): our perspective so we don't own Sandisc, uh in fact we don't own any memory names. Um

17:34Unidentified speaker (UNKNOWN): the the

17:34Unidentified speaker (speaker_1): question whether or not Sandisc Sandus is gonna do well from here is really contingent on whether or not memory remains a bottleneck within the semiconductor investment cycle. Second, um whether or not spending uh sustains at these levels or accelerates from here. We don't have a differentiated perspective, um, and so we're on the sidelines.

17:57Unidentified speaker (speaker_0): All right. We have an email from Pete who asks good afternoon. Could Julian provide? an update on Stonex? Thank you.

18:05Unidentified speaker (speaker_1): Sure. So for context, Stonex is a financial services company. They essentially do um trading uh on behalf of clients and in commodities, foreign exchange. Um and the company has grown through uh acquisitions. Uh think of them as kind of a market maker. They tend to do quite well. Um in periods of market volatility, especially within the comma commodity ecosystem. More trading is good for Stone X. So we own Stone X several months ago, we reduced our position in our portfolio, partly in recognition of the fact that the valuation had moved up a little bit, partly in recognition. recognition that uh the stock had done extremely well in the previous uh 12 or 18 months or so. Um but we like the company, uh they've made a series of acquisitions in recent months, and uh in line with history, we think that those acquisitions, when they consolidate the back office, start offering um uh products to the different clients of the of the acquired companies will be a creative, uh we'll be a creative. So we like

19:19Stonex, um, but we recognize that it has run up uh a lot and we trimmed and that's where we are.

19:26Unidentified speaker (speaker_0): Alright, excellent. We have another email. This one is from Ken who says, Hello, could I please get your guest's opinion on Eli Lilly and the healthcare sector in general? Thank you, Ken.

19:38Unidentified speaker (speaker_1): Understood. Uh Thanks, Ken. Thanks for the question. Eli Lilly, we own it. In our U.S. large cap portfolio, it's done quite well, I think for two reasons. The first is fundamentally they're executing well within their portfolio. People think of it as a GLP1 company, but we think that the remote moat extends beyond GLP1s. And in terms of healthcare more broadly, we think that the current environment is quite positive for the sector, which ties into the second reason. Like Lily, there's a great deal of innovation within the sector. AI has actually become an enabler of innovation if you think about cross- cross-referencing academic research papers and testing different hypotheses prior to actually doing executing them in a lab. And so we talk to sort of certainly our management teams of the companies we own, but we also talk to private companies. And they are relative to other sectors we've talked to, they are very, very optimistic about the prospects of AI within their industry, and they're all really talking about how it's

20:56helping them on the innovation front. So fundamentally, healthcare is doing well. If you look at valuations within the sector across the board, yes, the the likes of Lily trade at a deserved premium to the market, but there are quite a few healthcare companies that are rel reasonably inexpensive. And so that sort of is supportive.

21:18Unidentified speaker (UNKNOWN): Who are

21:18Unidentified speaker (speaker_0): the leaders in using AI for health purposes in your mind?

21:22Unidentified speaker (speaker_1): Who are the leaders within the industry? We think it's broad based. I think if you look at within the RD departments at the different companies, they're saying that they're using AI quite aggressively, but then also within the private and the VC ecosystem, you have a lot of companies that are able to start and develop ideas without as much sort of human capital. Additionally, some of the Frontier labs have started making investments in the healthcare space. So let's say it's it's really broad-based. And the reason being ultimately healthcare is an industry of trial and error. And AI allows you to make a lot more trials and errors via simulation and ultimately doing those trials in the real world. So we're optimistic about the prospects of the sector. Remember, it was very weak uh over the last post-COVID. And so we're getting a bit of that post-COVID recovery. Um and lastly

22:28in an environment where um there's a lot of geopolitical noise healthcare is a reasonably good place of refuge and that's also what we've seen in terms of the sector's relative performance vis-a-vis the broader market.

22:41Unidentified speaker (speaker_0): Mm-hmm. All right.

22:43Unidentified speaker (UNKNOWN): We're

22:43Unidentified speaker (speaker_0): gonna take a quick break there. When we return we'll take a look at Julian's past picks. That's next. Time now for past picks. And for this pick, we've got Citigroup on the list for Julian. He made that bet back in February 10th of 2026. And ooh, Julian, it's pretty. it's pretty flat.

23:17Unidentified speaker (speaker_1): Yes, it's flat. Um well financials don't perform well in an environment where um there's a lot of sort of geopolitical and economic uncertainty. So back in February, certainly didn't anticipate that we'd have uh a war uh in the Middle East and that inflation would be uh this high.

23:38Unidentified speaker (UNKNOWN): Um

23:38Unidentified speaker (speaker_1): but we continue to own it and uh we like it and the reason we like it is because it's a turnaround story and we believe that the turnaround is is unfolding as one would expect. So when you have a stock there's really two ways it goes against you. The first is external events, macro, the markets and and and the other is sort of fundamental company self-inflicted poor decisions. In this case, there are no company self-inflicted poor decisions. Uh the valuation is still attractive in our mind, and so we think it's a matter of time before the stock resumes higher.

24:21Unidentified speaker (speaker_0): Alright. All right. Next on your list we have Merck,

24:24Unidentified speaker (speaker_1): kind

24:24Unidentified speaker (speaker_0): of playing on your healthcare bet. uh we've been talking about during the show. So well that's up about twenty-three percent total return. So that healthcare bet's still still working out for you.

24:35Unidentified speaker (speaker_1): Yeah, so so in in this case, back in February, our view was that Keetruda, which is their which is their leading oncology drug, which accounts for forty percent of revenues today, um is uh on the cusp of a loss of exclusivity, meaning a patent cliff. And uh the market's concern was that they wouldn't be able to substitute those revenues. Um as you look at the other drugs that they have in their pipeline or the other drugs that they've launched recently, um, we share a different view. We're actually optimistic that the company can replace Keytruda and uh the internal engine of innovation within within Merck is quite strong. And so um I think the market has started to appreciate some of that perspective. And uh we think it continues.

25:27Unidentified speaker (speaker_0): So you think it'll continue rising? Do you all are you also very bullish on their AI advancements?

25:34Unidentified speaker (speaker_1): I would say they use it like their peers. Uh we actually met them recently. Um Yeah, they use it and we'll see how it sort of pans out in terms of innovation. W healthcare is all about making bets. Most of those bets won't work out. AI allows you to make more bets at a fairly small cost. And ideally even if the same percentage of bets work out, you're on a net basis better off.

26:03Unidentified speaker (speaker_0): Finally on your list we've got Celestica. Now

26:06Unidentified speaker (UNKNOWN): they

26:06Unidentified speaker (speaker_0): had a really great last quarter but uh down about 18%

26:10Unidentified speaker (speaker_1): since

26:11Unidentified speaker (speaker_0): your February call.

26:12Unidentified speaker (speaker_1): Yes. Yeah so I think it's a combination of the fact that uh concerns around uh the AI spending have increased substantially um and many many companies in the group have suffered significantly, despite, as you acknowledged, a good fundamentals. The second is they did do a small equity raise, they did do an equity raise later in the year, and so I think tapping the capital markets uh weight on the stock. From our perspective, they're gonna going to benefit substantially even if spending were to peak. here. And where the valuation is, we don't think it fully reflects the prospects of the company. Again, the sector is under pressure. There's a lot of concerns. People are shooting first and asking questions later. I think this is where, if you have an understanding of the company's roadmap, why they raise capital,

27:13Unidentified speaker (UNKNOWN): the

27:13Unidentified speaker (speaker_1): fact that they're reasonable. reasonably conservative with their guidance, the price is just a function of time.

27:20Unidentified speaker (speaker_0): All right. Let's take a pause there. We'll be back with Julian Nono Wam Dim of Goodread Investment Council taking your questions on U.S. equities.

27:59Unidentified speaker (UNKNOWN): We

27:59Unidentified speaker (speaker_0): We've got an email from Sam. Let's check in on. Sam. He wants his the guest's view on Microsoft.

28:07Unidentified speaker (speaker_1): Microsoft. So we own it, we like it. From our perspective, you may note that Microsoft was probably weak late last year, early into this year, and the shares have recovered. The debate was likely in our mind what does Microsoft look like in an H. agentic world? Um in an AI world. And once agentic AI actually emerged, it became clear that you're likely not going to replace the operating system for um the enterprise. But you may have agents or you may have some kind of solution that sits on top of Microsoft. So the terminal value risk to the business in an AI world has gone down in recent months. And that's something that we recognize, which allowed us to hold through the volatility. Today, the next layer of risk is well, what does Microsoft look like in a world where Anthropic has an Excel alternative?

29:09Unidentified speaker (UNKNOWN): I

29:09Unidentified speaker (speaker_0): just wanted to say, I mean, Anthropic is really putting Microsoft in a corner here. They want to go after their business.

29:15Unidentified speaker (speaker_1): Yeah, well, from our perspective, uh the profit pool for Microsoft is the enterprise. Um Google had Google Sheets, and at the time people were also a bit existential about the future of Microsoft, and here we are several years later, nothing has happened. Use that analogy for anthropic. Yes, having solutions are useful, but ultimately Microsoft has the enterprise customer and serves a whole host of functions within the enterprise. It is highly unlikely that a CTO removes Microsoft with other providers that have piecemeal solutions. So until we reach a point where there is a credible alternative that can serve the enterprise across the stack, we don't think that this is a structural threat.

30:10Unidentified speaker (speaker_0): Okay. We have an email from Emil who asks, Can I have your opinion on booking.com? That's BKNG. It's been under pressure for the last six months. And just wondering if you feel that AI is the issue or is it the consumer?

30:26Unidentified speaker (speaker_1): Yeah, so from our perspective, uh we own booking. It has certainly been under pressure, and we've been debating it internally and trying to figure out what's really going on. Um

30:38Unidentified speaker (UNKNOWN): we

30:39Unidentified speaker (speaker_1): don't think it's AI. Um, yes, there's debate around agentic AI booking uh hotels for people that want to travel, et cetera. And what does that mean for what does that mean for? BKNG? We think that the biggest issue that's pressuring the stock has to do with the onset of the war, which uh has impacted um people's traveling uh intentions globally. I mean even in North America, I'm sure you have anecdotes of people who were are thinking about going to Europe or the Middle East and have thought their travel plans So we think that it has more to do with the current environment. The stock has gone through periods like this in the past, where we remain optimistic and why we continue to own the stock is that both the margins and the free cash flow generation are strong. We think that structurally, particularly in Europe, which is our core market, technological advancement advancement, it's still is still behind, and they'll continue to serve as an as an in-between between hotels and the end customer.

31:45Unidentified speaker (speaker_0): Okay. Another email. The inbox, Sue in Chatham, Ontario asks, is Apple too expensive from a valuation perspective?

31:55Unidentified speaker (UNKNOWN): So

31:55Unidentified speaker (speaker_1): very good question.

31:58Unidentified speaker (UNKNOWN): It's

31:58Unidentified speaker (speaker_1): a very, very good question because we actually wrestle with that. Is Apple expensive relative to history? Absolutely. The question then becomes well, okay, it's expensive relative to what? What are the alternatives? If you're going to be invested, you're going to Apple or another company, or you might not be invested at all. But relative to the alternatives, when you think about the uh the hyperscalers and the amount of CapEx that they're spending. for AI, when you put that into the equation, you realize that the fact that Apple deliberately decided to stay out of the spending race and take the view that models would become commoditized and eventually they'd pick sort of the best models or partner and and what have you. When you think about that decision, you then then realize why the market is allowing the valuation to run much much hotter so we are concerned with

32:59the valuation um but in light of the fact that other alternatives are also expensive on a free cash flow basis we continue to own the stock and we like it.

33:10Unidentified speaker (UNKNOWN): What

33:10Unidentified speaker (speaker_0): do you think of their haven status and their strategy to just stay out of the side stay on the sidelines?

33:17Unidentified speaker (UNKNOWN): Because they're

33:17Unidentified speaker (speaker_0): not making the huge AI cap capital expenditures that have put a lot of heat on other tech companies.

33:24Unidentified speaker (UNKNOWN): Right.

33:25Unidentified speaker (speaker_0): Yeah.

33:25Unidentified speaker (speaker_1): Yeah, I mean so every business has to decide where they think um their value proposition is where do they have the right to win? Apple historically and I think even presently have a great relationship with their customers. Their consumers like their products, they offer services alongside the physical product, and uh they have a great sort of supply chain. That's that's what the previous CEO was known for. Um they've had a change in leadership, partly in recognition that the hardware hasn't really evolved in in many years,

34:02Unidentified speaker (UNKNOWN): but they

34:02Unidentified speaker (speaker_1): they've decided to stay outside of the CapEx race because they believed, and they actually put out a paper, I think, two years ago saying that LLMs aren't intelligent. That's their view. That was their view then. I don't know if it's changed since. So they made a deliberate view or call that they thought the different models are going to gonna be commoditized, but more importantly, they probably believed that the best model isn't necessarily what's going to drive better customer outcomes for them. And so they've stayed out of the s uh they've stayed on the sidelines and frankly it's proven to be correct so far.

34:42Unidentified speaker (speaker_0): Okay. We'll be right back with Julian Nono Wamdam Wamden of Goodread Investment Council taking your questions on US equities after the break. Welcome back to Market Call. We've got Peter on the line from Sarnia, Ontario. Hello, Peter.

35:02Unidentified speaker (speaker_3): Hey, good uh afternoon, I guess it is. Uh thank you for taking my call. Uh and my call is about Google. I and uh as an investor in today's market, I don't um and uh worry about being uh saying I'm very confused about what's going on. Maybe you could shed some light about what's going on with Google and uh would you be an investor at this point? Thank you.

35:25Unidentified speaker (speaker_1): Confused. Um so I so

35:29Unidentified speaker (UNKNOWN): we

35:29Unidentified speaker (speaker_1): own Google, we like Google, we think that their roadmap um is quite solid. If you think about two or three years ago, people were saying that SER. search and Google would be net sort of AI losers, and that has proven to be incorrect. We think that they're net winners, in fact. From our perspective, the point of differentiation that Google has is the amount of consumer data that they have. So we think that their data stack is extremely strong and valuable. And on the chips chip side with their TPUs, we think that that is also a differentiated perspective, particularly in light of the fact that the industry is currently undergoing changes. And so Google will uh continue to be a strong uh winner in the broader AI ecosystem, but also their relationship with their consumers. consumer in our view is is positive. Some people talk about, you

36:31know, search and the can can canabalization of search. People are also concerned with YouTube uh and and and shifts away from YouTube um to things like TikTok. Talk From our perspective as a franchise, Google is currently subsidizing its consumers and the and and the franchise is still under monetizing. And so when you have a business that has a lot of reserve pricing power, that is something not to ignore.

37:05Unidentified speaker (speaker_0): Interesting. I also see that a lot of billionaires are walking away from Alphabet in Q3. They for instance Stalin Stanley Druckenmiller's uh family office selling every Alphabet Class A share.

37:19Unidentified speaker (speaker_1): Yes.

37:19Unidentified speaker (speaker_0): What what's going on here?

37:21Unidentified speaker (speaker_1): Well, on Stan specifically, uh, certainly an investor I admire quite a bit. Um, his style is uh faster. Um, he rotates his portfolio completely very often, and so I wouldn't infer anything about Google's medium to long term prospects by looking at that kind of turnover. That would be sort of my perspective on the activity. And if you take it even more broadly, across the industry, a lot of people have shorter term time horizons in terms of their investments. And that's where, for retail investors, sometimes there is a great deal of opportunity. if you can be patient when others

38:06Unidentified speaker (UNKNOWN): the

38:06Unidentified speaker (speaker_2): lights are twinkling, the playlist sparkling. IHERTH Holidays is here. Canada's home for Christmas music with non-stop best of favorites 24-7.

38:21Unidentified speaker (UNKNOWN): Turn it

38:21Unidentified speaker (speaker_2): up and unwrap the holidays everywhere you go. Just ask your smart speaker to play iHeart the Holidays or stream it anytime, anywhere, on the free iHeartRadio app.

38:38Unidentified speaker (speaker_1): Are uh anxious and fearful? That can be uh a very valuable source of alpha, particularly when you do it in the context of of good companies.

38:49Unidentified speaker (UNKNOWN): All

38:49Unidentified speaker (speaker_0): right. We're gonna take a quick break. When we return, we'll take a look at Julian's new topics.

39:14Unidentified speaker (UNKNOWN): And

39:14Unidentified speaker (speaker_0): join us tomorrow on Market Call. We've got Colin Sizinski. He'll be on the show. He's portfolio manager and chief market strategist at C I S I A, CIA Wealth Management, and we'll be taking your questions on technical analysis.

39:29Unidentified speaker (UNKNOWN): And if

39:29Unidentified speaker (speaker_0): you missed Market Call, check out our daily podcast. You can find it on iHeartRadio and other platforms. You can also watch full episodes on our YouTube channel.

39:40Unidentified speaker (UNKNOWN): All right,

39:40Unidentified speaker (speaker_0): time now for top picks. And Julian, on the top of your list, we've got TG Therapeutics. That's TGTX on the NASDAQ.

39:49Unidentified speaker (speaker_1): Yes, so TGTX, and as I mentioned earlier, we've been very encouraged by the innovation that's happening in in the healthcare space, and that's been for us a fantastic source of of sort of hunting. for ideas and finding compelling ideas. I'll I'll start with the risk because biotech is very risky, very volatile. So tread carefully. But in the case of TGTX, what excites us is the company has this drug, Briam V, which treats uh multiple sclerosis, which is an autoimmune disease. About two and a uh two 2.9 point nine million people globally have uh MS, about a million uh within the US. Historically, what the medical community thought uh was the best way uh to address MS was to target T cells. In fact, in recent years, B cells, which are white blood cells, uh, are the better form of attacking uh MS. Within mature B cells, there are these proteins. proteins that are known as C D20. And Briyamvi is in the category of therapies known as anti-C D20 drugs. And so they sort of attack mature B cells, which attack the immune system. And that end market

41:07is growing quite rapidly. And certainly in the case of MS, that's a category that grows in the mid mid-single single dish. digit. And the anti-CD20 categories are growing

41:20Unidentified speaker (UNKNOWN): in

41:20Unidentified speaker (speaker_1): the 20% plus range. TGTX is approaching a billion-dollar run rate revenue. And for us, the catalyst ahead is a phase three readout of Brium Briyamvi V for subcutaneous use, which would open up the market. to in-home use, and also ultimately the expansion to other indications. And so when in biotech, what you want is to find a class-leading drug, which we think Briyamvi is. You want optionality to either a bigger market and/or And or other indication, which we think uh Briyamvi Brian V also offers. And lastly, you want to be paying what you think is a reasonable uh valuation relative to what peak sales could be. And in this case, again, uh, we think that the valuation is appropriate relative to our estimates of peak sales and certainly sales over the next several years.

42:18Unidentified speaker (UNKNOWN): I

42:19Unidentified speaker (speaker_0): see in their last earnings uh announcement, they raised their revenue guidance to about $1 billion above consensus estimates. Do you know what goes into

42:26Unidentified speaker (UNKNOWN): the remote?

42:27Unidentified speaker (speaker_0): that?

42:27Unidentified speaker (speaker_1): Yeah, it was them raising essentially saying that they're going to get to that billion dollar, they're getting to that billion dollar run rate. Um, and that is driven by the strength of Briam V. I mean that the class has other drugs. So there's a drug from Roche, uh, there's a drug from Novartis that addresses the anti-C anti-CD20 D twenty uh category. But um we think that Briam V is differentiated in the results in terms of the earnings are starting to show.

42:57Unidentified speaker (speaker_0): All right. You have another healthcare stock pick on your list. This one is MedSpace, MedPace Holdings.

43:05Unidentified speaker (speaker_1): Correct.

43:06Unidentified speaker (speaker_0): So M E D P on the NASDAQ. Tell us why it's on your list.

43:10Unidentified speaker (speaker_1): Yeah, so when investing in uh biotech, you can either go directly to the biotech companies or you can sort of invest around the ecosystem. MedPace is a CRO. They essentially help biopharma companies conduct uh clinical research, uh phase one through phase four trials. So if you're if you're gonna launch a drug, you have to do extensive clinical trials as part of that clinical trial process. Obviously, you need trial patients, you need to have documentation going back and forth between the company and the different regulators around safety, around efficacy, et cetera. Historically, pharma and certain biopharma companies did that internally. Over the last 15-20 15, 20 years, much of that work has been out. outsourced, and so some of that outsourcing can be functional or the outsourcing can be full. MedPace is a very interesting company because they skew towards smaller and emerging biotechnology companies. So the

44:19companies that don't necessarily have the resources to do um the clinical trials in-house, and so they outsource pretty much everything. to a company like MedPace. And so from our perspective, the bullish uh case hinges on two things. First, structurally, we think that outsourcing is gonna be here to stay. We think that um cyclically um biopharma spending has recovered. If you look at VC spending, etc., et cetera, the indications are positive, and so. we like MedPace. Valuation is a bit high, but the premium valuation is justified.

44:56Unidentified speaker (speaker_0): And finally we have United Natural Foods on your list. It's uh and we've got about 30 seconds, so tell us briefly why it's on there.

45:03Unidentified speaker (speaker_1): They're an organic food distributor with uh uh whole foods is a core customer. Uh we see consumer preferences shifting towards uh organic and uh our analysts analyst just Justin has written extensively on it on our website. So perhaps go to the insights and section at uh goodread.

45:22Unidentified speaker (speaker_0): Julian, we appreciate you coming on the show. Thanks so much.

45:24Unidentified speaker (speaker_1): Thank you for having me.

45:26Unidentified speaker (speaker_0): And thank you for watching Market Call. We'll see you next

45:29Unidentified speaker (UNKNOWN): time. The

45:31Unidentified speaker (speaker_2): lights are twinkling. The playlist sparkling.

45:37Unidentified speaker (UNKNOWN): I

45:37Unidentified speaker (speaker_2): iHeart heard the holidays is here. Canada's home for Christmas music with non-stop festive favorites 24-7. Turn it up and unwrap the holidays everywhere you go. Just ask your smart speaker to play iHeart the Holidays or stream it anytime, anywhere on the free iHeartRadio iHeart Radio app.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights